Equibles does not estimate personal net worth.
Get an email with a short summary when Praxis Precision Medicines, Inc. publishes a filing, an earnings call transcript or a press release.
Get PRAX alertsMarcio Souza is recorded as Board Member at Praxis Precision Medicines, Inc. (PRAX) since January 1, 2020 and CEO at Praxis Precision Medicines, Inc. (PRAX). The newest filing on record that lists Marcio Souza as CEO and Board Member at Praxis Precision Medicines, Inc. (PRAX) is dated April 30, 2026. Earlier roles on record: Board Member at ClearPoint Neuro, Inc. (CLPT) until April 27, 2020 and Board Member at Spyre Therapeutics, Inc. (SYRE) until June 22, 2023. Spyre Therapeutics, Inc. reported in an 8-K filed June 23, 2023 that Marcio Souza resigned as Board and any respective committee of the Board, effective June 22, 2023. The proxy statement of Praxis Precision Medicines, Inc. reports total compensation of $8,708,648 for Marcio Souza in fiscal 2025, including a base salary of $659,200. Disclosed compensation is on record for 6 fiscal years. Marcio Souza has spoken on 7 earnings calls and 2 other investor events across 1 company, most recently for Praxis Precision Medicines, Inc. on August 6, 2026. Praxis Precision Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Praxis Precision Medicines, Inc. includes Timothy E. Kelly (CFO), Timothy Kelly (CFO), Megan Sniecinski (COO) and 6 others.
“on June 22, 2023, immediately prior to the effective time of the merger (“Effective Time”), Armen Shanafelt, Ph.D., V. Bryan Lawlis, Ph.D. and Marcio Souza, M.B.A. resigned from the Board and any respective committee of the Board to which they were members.”
“Three months ago, I told you this would be the year Praxis has become a commercial company. This quarter is the one where that stopped being a plan and started materializing into the organization.”
“I appreciate the invitation and being here today. I'm Mark Susan. Tim Kelly, our CFO, is here with us.”
“I appreciate the invitation and being here today. I'm Mark Susan. Tim Kelly, our CFO, is here with us.”
“Thank you, Dan, and good morning, everyone, and thanks for joining Praxis' first quarter 2026 conference call.”
“Let me start by saying that 2025 was a remarkable year for Praxis. It was marked with the breadth of significant clinical achievements and regulatory advance across our portfolio.”
2020-01-01–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 30, 2026
2021-01-01–2023-06-22
Start not stated–2020-04-27
Biotechnology · Healthcare
CEO, Board Member
2020-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Praxis Precision Medicines, Inc. (PRAX) | President and Chief Executive Officer | $659,200 | $8,708,648 |
| 2024 | Praxis Precision Medicines, Inc. (PRAX) | President and Chief Executive Officer | $640,000 | $13,427,668 |
| 2023 | Praxis Precision Medicines, Inc. (PRAX) | President and Chief Executive Officer | $625,000 | $2,120,512 |
| 2022 | Praxis Precision Medicines, Inc. (PRAX) | President and Chief Executive Officer | $625,000 | $6,028,078 |
| 2021 | Praxis Precision Medicines, Inc. (PRAX) | President and Chief Executive Officer | $570,834 | $10,905,820 |
| 2020 | Praxis Precision Medicines, Inc. (PRAX) | President and Chief Executive Officer | $385,417 | $11,741,959 |
